Logo image of SMED

SHARPS COMPLIANCE CORP (SMED) Stock Fundamental Analysis

NASDAQ:SMED - Nasdaq - US8200171010 - Common Stock - Currency: USD

8.75  +0.01 (+0.11%)

Fundamental Rating

2

Taking everything into account, SMED scores 2 out of 10 in our fundamental rating. SMED was compared to 102 industry peers in the Health Care Providers & Services industry. While SMED seems to be doing ok healthwise, there are quite some concerns on its profitability. SMED is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SMED had positive earnings in the past year.
SMED Yearly Net Income VS EBIT VS OCF VS FCFSMED Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M 10M 15M 20M

1.2 Ratios

Industry RankSector Rank
ROA 2.89%
ROE 4.19%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SMED Yearly ROA, ROE, ROICSMED Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 10 20

1.3 Margins

Industry RankSector Rank
OM -0.78%
PM (TTM) 3.25%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SMED Yearly Profit, Operating, Gross MarginsSMED Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 10 20 30

More info and screens

4

2. Health

2.1 Basic Checks

SMED does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SMED has been increased compared to 1 year ago.
Compared to 1 year ago, SMED has an improved debt to assets ratio.
SMED Yearly Shares OutstandingSMED Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M
SMED Yearly Total Debt VS Total AssetsSMED Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

SMED has an Altman-Z score of 5.14. This indicates that SMED is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.06 indicates that SMED is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 5.14
ROIC/WACCN/A
WACC8.79%
SMED Yearly LT Debt VS Equity VS FCFSMED Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 3.50 indicates that SMED has no problem at all paying its short term obligations.
A Quick Ratio of 3.03 indicates that SMED has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.03
SMED Yearly Current Assets VS Current LiabilitesSMED Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

SMED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -67.24%.
Measured over the past years, SMED shows a very strong growth in Earnings Per Share. The EPS has been growing by 312.69% on average per year.
SMED shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.16%.
Measured over the past years, SMED shows a quite strong growth in Revenue. The Revenue has been growing by 18.02% on average per year.
EPS 1Y (TTM)-67.24%
EPS 3Y687.4%
EPS 5Y312.69%
EPS Q2Q%-102.5%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y23.94%
Revenue growth 5Y18.02%
Sales Q2Q%-36.15%

3.2 Future

The Earnings Per Share is expected to grow by 21.25% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.23% on average over the next years.
EPS Next Y-96.71%
EPS Next 2Y-62.6%
EPS Next 3Y-24.65%
EPS Next 5Y21.25%
Revenue Next Year-19.46%
Revenue Next 2Y-8.94%
Revenue Next 3Y-2.26%
Revenue Next 5Y1.23%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SMED Yearly Revenue VS EstimatesSMED Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
SMED Yearly EPS VS EstimatesSMED Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SMED is valuated quite expensively with a Price/Earnings ratio of 46.05.
When comparing the Price/Earnings ratio of SMED to the average of the S&P500 Index (28.88), we can say SMED is valued expensively.
SMED is valuated quite expensively with a Price/Forward Earnings ratio of 100.92.
The average S&P500 Price/Forward Earnings ratio is at 21.20. SMED is valued rather expensively when compared to this.
Industry RankSector Rank
PE 46.05
Fwd PE 100.92
SMED Price Earnings VS Forward Price EarningsSMED Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 86.22
SMED Per share dataSMED EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

SMED's earnings are expected to decrease with -24.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.15
EPS Next 2Y-62.6%
EPS Next 3Y-24.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SMED!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SHARPS COMPLIANCE CORP

NASDAQ:SMED (8/22/2022, 8:00:03 PM)

8.75

+0.01 (+0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-11 2022-05-11/amc
Earnings (Next)09-13 2022-09-13/bmo
Inst Owners1.02%
Inst Owner Change0%
Ins Owners8.93%
Ins Owner Change0%
Market Cap170.01M
Analysts48.89
Price Target7.52 (-14.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 46.05
Fwd PE 100.92
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B 2.64
P/tB N/A
EV/EBITDA 86.22
EPS(TTM)0.19
EY2.17%
EPS(NY)0.09
Fwd EY0.99%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4.27
BVpS3.32
TBVpSN/A
PEG (NY)N/A
PEG (5Y)0.15
Profitability
Industry RankSector Rank
ROA 2.89%
ROE 4.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -0.78%
PM (TTM) 3.25%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 3.03
Altman-Z 5.14
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.24%
EPS 3Y687.4%
EPS 5Y312.69%
EPS Q2Q%-102.5%
EPS Next Y-96.71%
EPS Next 2Y-62.6%
EPS Next 3Y-24.65%
EPS Next 5Y21.25%
Revenue 1Y (TTM)18.16%
Revenue growth 3Y23.94%
Revenue growth 5Y18.02%
Sales Q2Q%-36.15%
Revenue Next Year-19.46%
Revenue Next 2Y-8.94%
Revenue Next 3Y-2.26%
Revenue Next 5Y1.23%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A